Latest Myos Corp (MYOSD) Headlines MYOS Corpo
Post# of 46
Posted On: 03/10/2014 5:56:18 PM
Latest Myos Corp (MYOSD) Headlines
MYOS Corporation Initiates Clinical Study of MYO-T12(R) in Adult Women
Marketwire - Thu Feb 27, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, today announced the initiation of its first clinical study of MYO-T12(R) in women. The study, led by Stacy Zamuido, Ph.D., Senior Scientist and Director of Research for the Department of Obstetrics and Gynecology at Hackensack University Medical Center, will determine the effect of MYO-T12(R) on blood chemistry in healthy adult females. The 20-patient clinical trial will also observe the effect of MYO-T12(R) on body mass index (BMI) and waist circumference in addition to other indices of muscle health.
MYOS Corporation Appoints Christopher Pechock to Its Board of Directors
Marketwire - Mon Feb 24, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"), announced today that it has appointed Christopher Pechock to its Board of Directors.
MYOS Corporation Announces Appointment of Robert C. Ashton, Jr., M.D., as Chief Medical Officer
Marketwire - Thu Feb 13, 6:35AM CST
MYOS Corporation (OTCBB: MYOSD), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"), announced the appointment of Robert C. Ashton, Jr., M.D. as Chief Medical Officer. Dr. Ashton will lead the Company's clinical research efforts and serve on the management committee and the joint research and development committee. Dr. Ashton will also be responsible for the indication expansion strategy for MYO-T12, now known as Fortetropin(TM) and sold under the brand name MYO-X(TM). MYOS plans to conduct further clinical studies of Fortetropin in the treatment of age-associated muscle loss and sarcopenia associated with chronic illnesses such as cancer and neurodegenerative disease.
MYOS Corporation Initiates Clinical Study of MYO-T12(R) in Adult Women
Marketwire - Thu Feb 27, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, today announced the initiation of its first clinical study of MYO-T12(R) in women. The study, led by Stacy Zamuido, Ph.D., Senior Scientist and Director of Research for the Department of Obstetrics and Gynecology at Hackensack University Medical Center, will determine the effect of MYO-T12(R) on blood chemistry in healthy adult females. The 20-patient clinical trial will also observe the effect of MYO-T12(R) on body mass index (BMI) and waist circumference in addition to other indices of muscle health.
MYOS Corporation Appoints Christopher Pechock to Its Board of Directors
Marketwire - Mon Feb 24, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"), announced today that it has appointed Christopher Pechock to its Board of Directors.
MYOS Corporation Announces Appointment of Robert C. Ashton, Jr., M.D., as Chief Medical Officer
Marketwire - Thu Feb 13, 6:35AM CST
MYOS Corporation (OTCBB: MYOSD), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"), announced the appointment of Robert C. Ashton, Jr., M.D. as Chief Medical Officer. Dr. Ashton will lead the Company's clinical research efforts and serve on the management committee and the joint research and development committee. Dr. Ashton will also be responsible for the indication expansion strategy for MYO-T12, now known as Fortetropin(TM) and sold under the brand name MYO-X(TM). MYOS plans to conduct further clinical studies of Fortetropin in the treatment of age-associated muscle loss and sarcopenia associated with chronic illnesses such as cancer and neurodegenerative disease.
(0)
(0)MedAvail Holdings Inc. (MDVLQ) Stock Research Links
Scroll down for more posts ▼